Immunotherapy Success Depends on More Than Tumor Cells: Why Local Complement C3 May Shape Treatment Efficacy
Studies in mice and lung cancer specimens indicate that complement C3 produced by tumor fibroblasts can prevent immunosuppressive myeloid cells from entering tumors and is associated with a better anti-PD-1 response; C3 in the blood, however, does not have the same effect.